NRX Pharmaceuticals, Inc.
NRXP
Positions held
Your positionsNRXP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $125.12M | Enterprise value | $99.18M | Trailing P/E | — | Forward P/E | -8.26 |
| PEG | — | Price / book | -722.50 | Beta | 2.07 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 46.6% | Operating margin | -5.9% |
| Profit margin | 0.0% | ROE | — | ROA | -64.0% | Debt / equity | — |
| Current ratio | 0.86 | Free cash flow | -$9.64M | Analyst recommendation | strong_buy | Mean target | $38.50 |
| 52w high | $5.06 | 52w low | $1.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | $1.0M | $0.2M | $0.0M | — |
| Op margin | -590.5% | -444.6% | -470.4% | -1662.8% | — | — |
| Net income | -$16.5M | -$1.4M | $0.4M | -$5.9M | -$17.6M | — |
| Gross margin | 38.7% | 40.9% | 58.5% | 59.9% | — | — |
| Gross profit | $0.4M | $0.4M | $0.6M | $0.1M | $0.0M | — |
| Operating income | -$6.5M | -$4.7M | -$4.6M | -$4.0M | -$3.7M | — |
- Revenue +3% vs prior quarter ($1.1M vs $1.1M).
- Gross margin 38.7% (was 40.9% prior quarter).
- Operating margin compressed to -590.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -1324.4% | — | — | — | — |
| Net income | -$28.6M | -$25.1M | -$30.1M | -$39.8M | — |
| Gross margin | 58.8% | — | — | — | — |
| Gross profit | $0.7M | $0.0M | — | — | — |
| Operating income | -$16.2M | -$18.5M | -$27.6M | -$44.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-24 · Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?
2026-09-11 · NRX Pharmaceuticals' HOPE Therapeutics to Deploy Zeta's TMS Robotic System
2026-09-08 · NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-08-18 · NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
2026-08-18 · NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ...
2026-08-17 · Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-08-15 · NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns